Download PDF
Thromb Haemost 1998; 80(02): 246-249
DOI: 10.1055/s-0037-1615182
Rapid Communication
Schattauer GmbH

Congenital Resistance to Activated Protein C in Patients with Lupus Anticoagulants: Evaluation of Two Functional Assays

Monica Galli
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo and Hemophilia and Thrombosis Center “A. Bianchi Bonomi”, IRCCS, Maggiore Hospital and University of Milano, Italy
,
Francesca Duca
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo and Hemophilia and Thrombosis Center “A. Bianchi Bonomi”, IRCCS, Maggiore Hospital and University of Milano, Italy
,
Luisa Ruggeri
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo and Hemophilia and Thrombosis Center “A. Bianchi Bonomi”, IRCCS, Maggiore Hospital and University of Milano, Italy
,
Guido Finazzi
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo and Hemophilia and Thrombosis Center “A. Bianchi Bonomi”, IRCCS, Maggiore Hospital and University of Milano, Italy
,
Barbara Negri
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo and Hemophilia and Thrombosis Center “A. Bianchi Bonomi”, IRCCS, Maggiore Hospital and University of Milano, Italy
,
Marco Moia
1   Divisione di Ematologia, Ospedali Riuniti, Bergamo and Hemophilia and Thrombosis Center “A. Bianchi Bonomi”, IRCCS, Maggiore Hospital and University of Milano, Italy
› Author Affiliations
Further Information

Publication History

Received 19 January 1998

Accepted after resubmission 10 April 1998

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

The R506Q mutation (“Factor V Leiden”) is responsible for the resistance to activated Protein C (aPCR), that is evaluated by coagulation tests. Such tests cannot be used in patients with lupus anticoagulants (LAs), due to the interfering effect exerted by these antibodies on “in vitro” phospholipid-dependent coagulation tests. For this reason, assays have been developed to evaluate aPCR that are insensitive to the presence of LA antibodies. We evaluated two such coagulation tests in the plasma of 82 consecutive patients with LAs. By polymerase chain reaction 3 patients (3.6%) were found heterozygous for the R506Q mutation. aPCR was evaluated by two clotting assays, proposed to be “insensitive” to the presence of LAs: 1. aPCR-tissue factor-based assay, using Factor V deficient plasma and 1:40 diluted test plasma; 2. aPCR-dRVVT-based assay with highly concentrated phospholipids. Their interassay coefficient of variation was 28% and 6.2%, respectively. Compared to the polymerase chain reaction analysis, the 2 tests displayed the following characteristics: sensitivity 67% vs 100%, specificity 92% vs 96%, positive predictive value 25% vs 50%, negative predictive value 99% vs 100%, respectively. Among LA patients without the R506Q mutation, 5 scored positive in the aPCR-tissue factor-based assay, 2 in the aPCR-dRVVT-based assay and another one in both assays. Our findings suggest that the aPCRdRVVT-based test is more reliable and sensitive than the aPCR-tissue factor-based one to the R506Q mutation in patients with LAs. Both assays, when negative, make unlikely the presence of the R506Q mutation. Polymerase chain reaction analysis remains, however, to be performed when either test is positive.

 

  • References

  • 1 Dahlbäck B, Carlsson M, Svensoon PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.. Proc Natl Acad Sci (USA) 1993; 90: 1004-8.
    CrossrefPubMedGoogle Scholar
  • 2 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C.. Nature 1994; 369: 64-7.
    CrossrefPubMedGoogle Scholar
  • 3 Kalafatis M, Bertina RM, Rand MD, Mann KG. Characterization of the molecular defect in factor V/R506Q.. J Biol Chem 1995; 270: 4053-7.
    CrossrefPubMedGoogle Scholar
  • 4 Hillarp A, Dahlbäck B, Zöller B. Activated protein C resistance: from phenotype to genotype and clinical practice.. Blood Reviews 1995; 9: 201-12.
    CrossrefPubMedGoogle Scholar
  • 5 Griffin JH, Evatt B, Widman C, Fernandez JA. Anticoagulant protein C pathway defective in a majority of thrombophilic patients.. Blood 1993; 82: 1989-93.
    PubMedGoogle Scholar
  • 6 Rees D. The population genetics of factor V Leiden (Arg506Gln).. Br J Haematol 1996; 95: 579-86.
    CrossrefPubMedGoogle Scholar
  • 7 Galli M, Finazzi G, Barbui T. Antiphospholipid antibodies: predictive value of laboratory tests.. Thromb Haemost 1997; 78: 75-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant.. Blood 1995; 85: 1704-11.
    PubMedGoogle Scholar
  • 9 Exner T, Murray B, Chong BH Chesterman CN. Improved aPC-resistance method based on a Russell viper venom clotting test.. Thromb Haemost 1995; 73: 1119 (abstract 839).
    PubMedGoogle Scholar
  • 10 Dizon-Townson D, Hutchinson C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid antibodies.. Thromb Haemost 1995; 74: 1029-31.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Martorell JR, Muñoz-Castillo A, Gil JL. False positive activated protein C resistance test due to anti-phospholipid antibodies is corrected by platelet extract.. Thromb Haemost 1995; 74: 796 (letter).
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Villa P, Aznar J, Jorquera JI, Casaña P. Laboratory diagnosis of aPC-resistance in patients with lupus anticoagulant.. Thromb Haemost 1995; 74: 1606-7 (letter).
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Aboud MR, Ma DDF. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.. Br J Haematol 1997; 97: 798-803.
    CrossrefPubMedGoogle Scholar
  • 14 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update.. Thromb Haemost 1995; 74: 1185-90.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.. Br J Haematol 1978; 40: 143-51.
    CrossrefPubMedGoogle Scholar
  • 16 Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper viper venom time for the diagnosis of lupus anticoagulants.. Blood 1986; 68: 869-74.
    PubMedGoogle Scholar
  • 17 Triplett DA, Stocker KF, Unger GA, Barna LK. The Textarin/Ecarin ratio: a confirmatory test for lupus anticoagulants.. Thromb Haemost 1993; 70: 925-31.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by enzyme-linked immunosorbent assay: standardization and quantitation of results.. Clin Exp Immunol 1985; 62: 738-44.
    PubMedGoogle Scholar
  • 19 Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies.. Thromb Haemost 1997; 77: 486-91.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Mannucci PM, Duca F, Peyvandi F, Tagliabue L, Merati G, Martinelli I, Cattaneo M. Frequency of Factor V Arg 506 Gln in italians.. Thromb Haemost 1996; 75: 694 (letter).
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Freyburger G, Javorschi S, Labrouche S, Bernard P. Proposal for objective evaluation of the performance of various functional aPC-resistance tests in genotyped patients.. Thromb Haemost 1997; 78: 1360-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Mannucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.. Blood 1997; 90: 1552-7.
    PubMedGoogle Scholar
  • 23 Galli M, Ruggeri L, Barbui T. Differential effects of anti-β2-glycoprotein I and anti-prothrombin antibodies on the anticoagulant activity of activated protein C.. Blood 1998; 91: 1999-2004.
    PubMedGoogle Scholar
  • 24 Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant.. Blood 1989; 74: 2426-32.
    PubMedGoogle Scholar
  • 25 Martinuzzo M, Forastiero R, Adamezuk Y, Cerrato G, Carreras LO. Activated protein C resistance in patients with anti-β2-glycoprotein I antibodies.. Blood Coagul Fibrinol 1996; 7: 702-4.
    CrossrefPubMedGoogle Scholar
  • 26 Montaruli B, Schinco P, Pannocchia A, Giorgianni A, Borchiellini A, Tamponi G, Pileri A. Use of modified functional assays for activated Protein C resistance in patients with basally prolonged aPTT.. Thromb Haemost 1997; 78: 1042-8.
    Article in Thieme ConnectPubMedGoogle Scholar